Nitisinone
CAS : 104206-65-7
Ref. 3D-FN26231
1g | Arrêté | ||
2g | Arrêté | ||
5g | Arrêté | ||
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté | ||
250mg | Arrêté | ||
500mg | Arrêté |
Informations sur le produit
- 2-[2-Nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione
- 1,3-Cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]-
- 2-[2-Nitro-4-(Trifluoromethyl)Benzoyl]Cyclohexane-1,3-Dione
- Nitisone
- Nityr
- Orfadin
- Sc 0735
Nitisinone is a drug that is used to treat hereditary tyrosinemia type I, which is an autosomal recessive metabolic disorder. It works by blocking the synthesis of tyrosine, one of the amino acids needed for human cell growth and function. Nitisinone has been shown to improve liver function in patients with chronic hepatitis B virus infection or chronic hepatitis C virus infection. Nitisinone also blocks the production of monoamine neurotransmitters and may be effective against renal cell cancer. Nitisinone has been shown to have a molecular pathogenesis that can be described as follows:
NITISINONE → TYROSINE → L-DOPA → DOPAMINE (BLOCKS)